Updates in Low-Grade and Aggressive Lymphomas is a CME-accredited OncoBlast activity designed to help oncology professionals apply the latest advances in lymphoma care through interactive, case-based learning. Using clinical scenarios and knowledge checks, learners will review current standards and emerging therapies for both indolent and aggressive lymphomas, including antibody-drug conjugates, bispecific antibodies, BTK and BCL2 inhibitors, and CAR T-cell therapy. This microlearning activity emphasizes a multidisciplinary, patient-centered approach, equipping participants to integrate new evidence into real-world decision-making, recognize therapy-specific toxicities, and optimize treatment outcomes across diverse patient populations.
Course Accreditations
Course Summary
| Events Starts | Events Ends |
|---|---|
| 10/20/2025 | 12/31/2025 |
Faculty
Praveen Ramakrishnan (MD, MS, MBA, FACP)
Dr. Ramakrishnan currently serves as the Director of the Aggressive Lymphoma Program at UT Southwestern Medical Center. His clinical research focuses on targeted and cellular therapies in lymphoid malignancies. He is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Hematology and Oncology. In addition, he serves as the Medical Director of the Infusion Center and Acute Care Center (SAC) at the Harold C. Simmons Comprehensive Cancer Center. Originally from India, Dr. Ramakrishnan received his initial medical training at the Medical College, Trivandrum, University of Kerala, followed by residency training in Internal Medicine at the Jawaharlal Institute of Medical Education and Research (JIPMER) in Puducherry. He completed advanced training in Hematology and Medical Oncology at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania, where he also earned a master’s degree in Pharmacology through the NIH K30 Training Program in Human Investigation. Board-certified by the American Board of Internal Medicine in internal medicine, hematology, and medical oncology, Dr. Ramakrishnan joined the UT Southwestern faculty in 2017. He is an active member of several professional organizations, including the American College of Physicians, American Medical Association, American Society of Clinical Oncology, American Society of Hematology, American Society for Blood and Marrow Transplantation, American Association for Cancer Research, American Association for the Advancement of Science, and the International Primary CNS Lymphoma Collaborative Group.
Disclosure
Financial relationships Attribution: Self Type of financial relationship: Professional Services Ineligible company: Kite/ Gilead Topic: Advisory Board Date added: 05/16/2025 Date updated: 05/16/2025 Attribution: Self Type of financial relationship: Professional Services Ineligible company: BMS Topic: Advisory Board Date added: 05/16/2025 Date updated: 05/16/2025 Attribution: Self Type of financial relationship: Professional Services Ineligible company: Acrotech Biopharma Topic: Advisory Board Date added: 05/16/2025 Date updated: 05/16/2025 Attribution: Self Type of financial relationship: Professional Services Ineligible company: ONO Pharma Topic: Advisory Board Date added: 05/16/2025 Date updated: 05/16/2025 Attribution: Self Type of financial relationship: Professional Services Ineligible company: IPSEN Pharma Topic: Advisory Board Date added: 05/16/2025 Date updated: 05/16/2025 Attribution: Self Type of financial relationship: Professional Services Ineligible company: ADC Therapeutics Topic: Advisory Board Date added: 05/16/2025 Date updated: 05/16/2025
- Medical oncologists
- Oncology residents/fellows
- Oncology NPs/PAs
- Oncology pharmacists
Target Audience
- Discuss new and updated treatment options for patients with lymphomas.
- Identify side effects, indications, and contra-indications of therapies used to diagnose and treat lymphomas.
- Explain how to effectively manage side-effects associated with lymphoma treatment.
Learning Objectives
Upon successful completion of this educational activity, participants will be able to: